Navigation Links
Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)

CHAPEL HILL, N.C., May 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Cempra with a five year contract valued up to $58 million for the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens.  Solithromycin, Cempra's lead product candidate, is a fourth generation macrolide antibiotic in the fluoroketolide family that is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults.  The company will host a conference call and webcast at 8:30 a.m. EDT, tomorrow, May 29, to discuss the agreement.

"We are delighted that BARDA has recognized solithromycin as a potentially safe and effective treatment for the pediatric population," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. "Macrolides have traditionally been favored for use in pediatrics because of their safety and efficacy.  Solithromycin's approval would be the first orally administered antibiotic approved in decades, and azithromycin (Zithromax® or Z-Pak) was the last macrolide approved, which was in 1991.  We view BARDA's funding of this project as recognition of the potential of solithromycin to have broad utility in all age groups."

The upfront contract is for a two year base period with guaranteed funding of $17.7 million and is extendable up to five years bringing the value of the total contract to $58 million.  The contract is expected to fund a variety of activities that are planned to lead to the Pediatric as well as the Animal Rule New Drug Applications (NDA) for use of solithromycin against bioterror threat pathogens. The full funding, if received, will support Phase 1, Phase 2, and the majority of the Phase 2/3 studies on a pediatric oral suspension, oral capsules and the intravenous formulation for CABP. The contract should also fund non-human primate pilot studies of activity against biothreat pathogens, anthrax and tularemia, placing Cempra's lead product on the pathway to other indications.

This project will be funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201300009C.

Conference Call and Webcast
The conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., BARDA Contract Award Conference Call, conference ID#: 77304813." The conference call will be webcast live under the investor relations section of Cempra's website at, and will be archived there for 30 days following the call. Please visit Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases.  Cempra's two lead product candidates are currently in advanced clinical development.  Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan.  TAKSTA™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at

Investor and Media Contacts:
Robert E. Flamm , Ph.D.
Russo Partners, LLC
(212) 845-4226

Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4235

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; the results of studies and trials of our product candidates conducted by others; our anticipated capital expenditures and our estimates regarding our capital requirements; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; and innovation by our competitors. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.


SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
2. Cempra to Present Data on Solithromycins (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
3. Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
4. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
5. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
6. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
7. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
8. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
9. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
10. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
11. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
Post Your Comments:
(Date:11/30/2015)... September 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... , 2,917 , (3.3) Gross Profit 395,857 ...
(Date:11/30/2015)... November 30, 2015 --> ... "Dental Lasers Market by Product (Soft Tissue, All Tissue, Dental ... (Hospitals, Clinics), and Geography - Global Forecast to 2020", published ... 2020, at a CAGR of 5.2% during the forecast period ... data Tables and 62 Figures spread through 167 P ...
(Date:11/30/2015)... 2015  PTS Diagnostics, the U.S.-based manufacturer of point-of-care ... A1CNow ® systems, and PTS Detect™ cotinine systems, ... that will propel the company into the mHealth market. ... Europe . The technology is a system that ... smartphones and tablets, and uses test strip technology already ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... During the National Family Caregivers Month, the ... webinars on topics of ‘Medical and Palliative Care Decisions,’ and ‘Self-Care for Caregivers.’ ... , With a loved one's diagnosis of mesothelioma, the closest family member is ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase awareness of ... Your Mouth?” campaign to inform dentists that the technicians they trust could lack ...
(Date:11/30/2015)... ... November 30, 2015 , ... An extensive ... is specialized and only includes chiropractic clinics in the US. , The team ... alternative health practitioner when back pain sets in. When people are experiencing back ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
(Date:11/30/2015)... Flint, Michigan (PRWEB) , ... November 30, 2015 ... ... a safe and fun atmosphere for Halloween festivities, the Word of Life Christian ... classic children’s board game, and featuring a giant 1.25 ton pile of candy ...
Breaking Medicine News(10 mins):